Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology (NYSE American: MAIA) reported initial efficacy data from Part C of its Phase 2 THIO-101 expansion trial in third-line advanced non-small cell lung cancer.
Ateganosine followed by cemiplimab achieved a 90.5% disease control rate (19/21 patients) in an efficacy-evaluable, heavily pre-treated population, with an acceptable safety profile and completed international enrollment.
MAIA Biotechnology (NYSE American: MAIA) completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial of ateganosine in third-line non-small cell lung cancer. Part C randomized 41 CPI- and chemotherapy-resistant patients to ateganosine plus cemiplimab or ateganosine alone.
According to MAIA, Parts A and B showed median survival of 17.8 months versus expected 5.8 months, with eight patients living beyond two years and one over 33 months. The FDA has granted Fast Track designation for ateganosine in NSCLC.
MAIA Biotechnology (NYSE American: MAIA) has opened patient enrollment at Winship Cancer Institute of Emory University, the third U.S. site in its Phase 2 THIO-101 expansion trial.
The open-label study evaluates telomere-targeting agent ateganosine followed by cemiplimab as third-line treatment for NSCLC patients resistant to checkpoint inhibitors and chemotherapy, a setting with no FDA-approved options. According to MAIA, earlier trial parts showed strong early efficacy, with some patients’ survival exceeding two years.
MAIA Biotechnology (NYSE American: MAIA) activated its second U.S. clinical site for the international Phase 2 THIO-101 expansion trial at Central Alabama Research in Homewood, Alabama. The study evaluates lead therapy ateganosine as third-line treatment for NSCLC patients who failed checkpoint inhibitors and chemotherapy.
The THIO-101 expansion now has 44 active sites in 6 countries plus 2 in the U.S., and may support an accelerated FDA approval filing. MAIA is also enrolling a pivotal Phase 3 trial assessing overall survival in up to 300 patients, under an FDA Fast Track designation.
MAIA Biotechnology (NYSE American: MAIA) reported enrollment progress in its pivotal Phase 3 THIO-104 trial of telomere-targeting therapy ateganosine for third-line advanced non-small cell lung cancer.
According to MAIA, 29 patients have been dosed across 34 sites in 6 countries, with a target of up to 100 patients by year-end and an interim survival analysis expected in 2027. Prior Phase 2 THIO-101 data showed median overall survival of 17.8 months versus 5.8 months with chemotherapy. Ateganosine has FDA Fast Track designation and is positioned within a projected $70 billion global NSCLC market by 2030.
MAIA Biotechnology (NYSE American: MAIA) received FDA clearance of an amended IND, allowing U.S. enrollment in the expanded Phase 2 THIO-101 trial of lead candidate ateganosine for advanced third-line NSCLC.
The trial runs alongside pivotal Phase 3 THIO-104 and spans 44 sites across six countries.
MAIA Biotechnology (NYSE American: MAIA) reported insider open market share purchases by its founder and CEO Vlad Vitoc and Director Stan V. Smith.
Vitoc bought about 72,700 shares at $1.3877 and Smith about 75,000 shares at $1.336 on June 6, 2026, bringing directors and officers’ ownership to 20.46%. The company is advancing its telomere-targeting immuno-oncology platform, including the ateganosine program for advanced non-small cell lung cancer.
MAIA Biotechnology (NYSE American: MAIA) presented a Trial in Progress poster at the 2026 ASCO Annual Meeting detailing its pivotal Phase 3 THIO-104 study. The trial evaluates telomere-targeting agent ateganosine (THIO) sequenced with a checkpoint inhibitor in third-line, CPI- and chemotherapy-resistant NSCLC patients.
First dosing occurred in December 2025, with screening and enrollment ongoing in Europe and Asia.
MAIA (NYSE:MAIA) activated its first U.S. clinical site (Summit Medical Group, NJ) for the Phase 2 THIO-101 expansion in third-line non-small cell lung cancer (3L NSCLC) on April 16, 2026.
The expansion adds U.S. access (four more U.S. sites planned in 2026) to a program with 44 active sites in six countries, a $2.3M NIH grant, FDA Fast Track designation, and reported overall survival beyond 24 months for eight patients.
MAIA (NYSE American: MAIA) announced that net proceeds from its March 2026 common stock offering of $33 million are expected to fully fund its ongoing pivotal Phase 3 trial of ateganosine in third-line non-small cell lung cancer (3L NSCLC).
The FDA granted Fast Track designation for ateganosine in 3L NSCLC. THIO-104 is a global, multicenter, open-label, randomized 1:1 trial of up to 300 patients comparing ateganosine plus a checkpoint inhibitor to chemotherapy; interim Phase 3 data are expected next year.